Your Health, We Care
Release date: 2026-01-23 17:25:52 Article From: Lucius Laos Recommended: 10
The price of lorlatinib varies significantly, mainly depending on the drug source (innovator or generic), availability of medical insurance reimbursement, and purchase channel.
The price of domestic innovator drugs is relatively low after medical insurance reimbursement, while it is quite high without reimbursement. The prices of overseas generic drugs are generally more affordable, but attention should be paid to the legitimacy of their sources and efficacy differences.
After medical insurance reimbursement: The price is cost-effective, and it can be further reduced in some regions through special reimbursement policies.
Self-paid price: Without medical insurance coverage, the price is high, imposing a heavy economic burden.
The following are common market quotations (all with the specification of 100mg × 30 capsules):
Laotian generics: Affordable prices with stable supply channels.
Bangladeshi generics: Moderate prices, with some channels offering a relatively low starting price.
Indian generics: Prices fluctuate greatly; caution is needed to verify the reliability of the channel when individual platforms quote extremely low prices.
Turkish innovator version: Priced lower than the Hong Kong innovator version.
Impact of medical insurance: Domestic prices are directly linked to medical insurance policies, and the reimbursement ratio varies by region. Consult local hospitals or medical insurance authorities for details.
Risks of generic drugs: Overseas generic drugs have not been approved for marketing in China. Purchasing them via agents involves legal and medication safety risks (e.g., ingredient discrepancies, transportation and storage issues), so a trade-off between pros and cons is required before purchase.
Medical advice: Lorlatinib must be used strictly in accordance with medical prescriptions. Unauthorized replacement of drug sources may affect the therapeutic effect. It is recommended to obtain the drug through formal medical institutions and confirm the drug qualification before purchase.
Note: The above price information is for reference only. The actual cost is subject to exchange rate fluctuations, channel variations and policy adjustments, and shall be based on real-time conditions.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3652024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：892025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：922025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
